BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Influencers are selling a delusional fantasy of being postpartum. Why is it so easy to believe? - 26 Asian Urban areas to Visit
- 3SpaceX launches Starlink satellites on its 150th Falcon 9 mission of the year
- 4Heartfelt Objections to Visit with Your Adored One
- 5The Green Transformation: 5 Feasible Living Practices
- US EPA will reassess safety of herbicide paraquat, says its chief
- Doulas play essential roles in reproductive health care – and more states are beginning to recognize it
- Scientists sent a menstrual cup to space. This is how it went
- Excursion to Different Universes: the Top Sci-fi Motion pictures Ever
- Southern Californians, your health insurance costs could rise in 2026
- Share your pick for the tree that you love for its novel magnificence!
- Over 250,000 cases of shredded cheese recalled over possible metal fragments
- Vote In favor of Your Favored Sort Of Bevarage
- What to know about voluntary chocolate recall
